GSK to pay Tolerx $15M for study of diabetes drug

08/7/2008 | American City Business Journals

Tolerx started a late-stage clinical study of otelixizumab that involves 240 adults with new-onset Type 1 diabetes. The biopharmaceutical firm will receive $15 million in a milestone payment from partner GlaxoSmithKline for the study, which is being conducted in North America and Europe.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ